1
|
Giorgioni G, Bonifazi A, Botticelli L, Cifani C, Matteucci F, Micioni Di Bonaventura E, Micioni Di Bonaventura MV, Giannella M, Piergentili A, Piergentili A, Quaglia W, Del Bello F. Advances in drug design and therapeutic potential of selective or multitarget 5-HT1A receptor ligands. Med Res Rev 2024. [PMID: 38808959 DOI: 10.1002/med.22049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 03/14/2024] [Accepted: 05/03/2024] [Indexed: 05/30/2024]
Abstract
5-HT1A receptor (5-HT1A-R) is a serotoninergic G-protein coupled receptor subtype which contributes to several physiological processes in both central nervous system and periphery. Despite being the first 5-HT-R identified, cloned and studied, it still represents a very attractive target in drug discovery and continues to be the focus of a myriad of drug discovery campaigns due to its involvement in numerous neuropsychiatric disorders. The structure-activity relationship studies (SAR) performed over the last years have been devoted to three main goals: (i) design and synthesis of 5-HT1A-R selective/preferential ligands; (ii) identification of 5-HT1A-R biased agonists, differentiating pre- versus post-synaptic agonism and signaling cellular mechanisms; (iii) development of multitarget compounds endowed with well-defined poly-pharmacological profiles targeting 5-HT1A-R along with other serotonin receptors, serotonin transporter (SERT), D2-like receptors and/or enzymes, such as acetylcholinesterase and phosphodiesterase, as a promising strategy for the management of complex psychiatric and neurodegenerative disorders. In this review, medicinal chemistry aspects of ligands acting as selective/preferential or multitarget 5-HT1A-R agonists and antagonists belonging to different chemotypes and developed in the last 7 years (2017-2023) have been discussed. The development of chemical and pharmacological 5-HT1A-R tools for molecular imaging have also been described. Finally, the pharmacological interest of 5-HT1A-R and the therapeutic potential of ligands targeting this receptor have been considered.
Collapse
Affiliation(s)
- Gianfabio Giorgioni
- Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Camerino, Italy
| | - Alessandro Bonifazi
- Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, Baltimore, Maryland, USA
| | - Luca Botticelli
- Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy
| | - Carlo Cifani
- Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy
| | - Federica Matteucci
- Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Camerino, Italy
| | | | | | - Mario Giannella
- Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Camerino, Italy
| | | | - Alessia Piergentili
- Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Camerino, Italy
| | - Wilma Quaglia
- Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Camerino, Italy
| | - Fabio Del Bello
- Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Camerino, Italy
| |
Collapse
|
2
|
Mokrov GV. Multitargeting in cardioprotection: An example of biaromatic compounds. Arch Pharm (Weinheim) 2023; 356:e2300196. [PMID: 37345968 DOI: 10.1002/ardp.202300196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 05/23/2023] [Accepted: 05/26/2023] [Indexed: 06/23/2023]
Abstract
A multitarget drug design approach is actively developing in modern medicinal chemistry and pharmacology, especially with regard to multifactorial diseases such as cardiovascular diseases, cancer, and neurodegenerative diseases. A detailed study of many well-known drugs developed within the single-target approach also often reveals additional mechanisms of their real pharmacological action. One of the multitarget drug design approaches can be the identification of the basic pharmacophore models corresponding to a wide range of the required target ligands. Among such models in the group of cardioprotectors is the linked biaromatic system. This review develops the concept of a "basic pharmacophore" using the biaromatic pharmacophore of cardioprotectors as an example. It presents an analysis of possible biological targets for compounds corresponding to the biaromatic pharmacophore and an analysis of the spectrum of biological targets for the five most known and most studied cardioprotective drugs corresponding to this model, and their involvement in the biological effects of these drugs.
Collapse
|
3
|
Wang WT, Qian H, Wu JW, Chen XW, Li JQ. Synthesis and antidepressant-like activity of novel alkoxy-piperidine derivatives targeting SSRI/5-HT 1A/5-HT 7. Bioorg Med Chem Lett 2019; 29:126769. [PMID: 31699607 DOI: 10.1016/j.bmcl.2019.126769] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2019] [Revised: 10/08/2019] [Accepted: 10/16/2019] [Indexed: 11/25/2022]
Abstract
A series of novel alkoxy-piperidine derivatives were synthesized and evaluated for their serotonin reuptake inhibitory and binding affinities for 5-HT1A/5-HT7 receptors. In vivo antidepressant activities of the selective compounds were explored using the forced swimming test (FST) and tail suspension test (TST) in mice. The results showed that compounds 7a (reuptake inhibition (RUI), IC50 = 177 nM; 5-HT1A, Ki = 12 nM; 5-HT7, Ki = 25 nM) and 15g (RUI, IC50 = 85 nM; 5-HT1A, Ki = 17 nM; 5-HT7, Ki = 35 nM) were potential antidepressant agents in animal behavioral models with high 5-HT1A/5-HT7 receptor affinities and moderate serotonin reuptake inhibition, and good metabolic stability in vitro.
Collapse
Affiliation(s)
- Wen-Tao Wang
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Shanghai 201203, PR China; School of Engineering, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, PR China.
| | - Hao Qian
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Shanghai 201203, PR China
| | - Jian-Wei Wu
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Shanghai 201203, PR China
| | - Xiao-Wen Chen
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Shanghai 201203, PR China
| | - Jian-Qi Li
- Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Shanghai 201203, PR China.
| |
Collapse
|
4
|
Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. Part 5. Eur J Med Chem 2015; 98:221-36. [PMID: 26043160 DOI: 10.1016/j.ejmech.2015.05.003] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2014] [Revised: 08/15/2014] [Accepted: 05/04/2015] [Indexed: 01/09/2023]
Abstract
A series of novel 4-aryl-pyrido[1,2-c]pyrimidine derivatives containing a 1-(2-quinoline)piperazine moiety was synthesized. The chemical structure of new compounds was confirmed by FT-IR, (1)H NMR, (13)C NMR and HRMS spectra as well as elemental analysis. Affinity of the novel pyrido[1,2-c]pyrimidine derivatives for 5-HT1A, 5-HT2A receptors and serotonin transporter (SERT) was evaluated in an in vitro radioligand binding assay. Tested compounds showed moderate to high affinity for 5-HT1AR and SERT and low affinity for 5-HT2AR. Selected ligands were subjected to in vivo tests, such as induced hypothermia and the forced swimming test in mice, which determined presynaptic agonistic activity of the ligands 8d, 8e, 9d and 9e and presynaptic antagonistic activity of the ligands 8a, 8b, 9a, 9b. Additionally, metabolic stability evaluation was performed for selected ligands, proving that a para-substitution in the 4-aryl-pyrido[1,2-c]pyrimidine moiety leads to an increase in stability, whereas a substitution in the ortho-position lowers the stability.
Collapse
|
5
|
Kushwaha K, Kaushik N, Lata, Jain SC. Design and synthesis of novel 2H-chromen-2-one derivatives bearing 1,2,3-triazole moiety as lead antimicrobials. Bioorg Med Chem Lett 2014; 24:1795-801. [PMID: 24594353 DOI: 10.1016/j.bmcl.2014.02.027] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Revised: 01/13/2014] [Accepted: 02/10/2014] [Indexed: 11/29/2022]
Abstract
A series of novel 2H-chromen-2-one derivatives decorated with 1,2,3-triazole moiety were designed and synthesized using the click reaction of azidoalkyloxy-2H-chromen-2-ones with different propargylamines. Propargylamines were obtained by alkylation of various heterocyclic amines with propargyl bromide. Newly synthesized compounds and intermediates were evaluated for their antifungal activity against four fungi (Aspergillus niger, Aspergillus fumigatus, Aspergillus flavus and Candida albicans). Antibacterial studies were also carried out against three Gram-positive bacteria (Staphylococcus aureus, Bacillus subtilis and Staphylococcus epidermis) and four Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Salmonella typhi and Klebsiella pneumoniae). In vitro, bioassay results showed that all the synthesized compounds exhibited excellent activity against fungal strains Aspergillus fumigatus, Aspergillus flavus and Candida albicans. Interestingly, all the compounds have shown even superior activity than the reference drug miconazole against Aspergillus fumigatus. Morpholine and N-acetyl piperazine containing compounds 10c and 10e have shown promising activity against various bacterial strains. Compound 10e was found to be most active against Pseudomonas aeruginosa. Based on, in silico pharmacokinetic studies, compounds 10a-e were identified as lead compounds for future investigation due to their lower toxicity, high drug score values and good oral bioavailability as per OECD guidelines.
Collapse
Affiliation(s)
- Khushbu Kushwaha
- Department of Chemistry, University of Delhi, Delhi 110 007, India
| | - Nagendra Kaushik
- Plasma Bioscience Research Center, Kwangwoon University, Seoul 139701, Republic of Korea
| | - Lata
- Department of Chemistry, University of Delhi, Delhi 110 007, India
| | - Subhash C Jain
- Department of Chemistry, University of Delhi, Delhi 110 007, India.
| |
Collapse
|
6
|
5-HT1A receptor pharmacophores to screen for off-target activity of α1-adrenoceptor antagonists. J Comput Aided Mol Des 2013; 27:305-19. [PMID: 23625023 DOI: 10.1007/s10822-013-9647-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2013] [Accepted: 04/13/2013] [Indexed: 01/08/2023]
Abstract
The α1-adrenoceptors (α1-ARs), in particular the α1A-AR subtype, are current therapeutic targets of choice for the treatment of urogenital conditions, such as benign prostatic hyperplasia (BPH). Due to the similarity between the transmembrane domains of the α1-AR subtypes, and the serotonin receptor subtype 1A (5-HT1A-R), currently used α1-AR subtype-selective drugs to treat BPH display considerable off-target affinity for the 5-HT1A-R, leading to side effects. We describe the construction and validation of pharmacophores for 5-HT1A-R agonists and antagonists. Through the structural diversity of the training sets used in their development, these pharmacophores define the properties of a compound needed to bind to 5-HT1A receptors. Using these and previously published pharmacophores in virtual screening and profiling, we have identified unique chemical compounds (hits) that fit the requirements to bind to our target, the α1A-AR, selectively over the off-target, the 5-HT1A-R. Selected hits have been obtained and their affinities for α1A-AR, α1B-AR and 5-HT1A-R determined in radioligand binding assays, using membrane preparations which contain human receptors expressed individually. Three of the tested hits demonstrate statistically significant selectivity for α1A-AR over 5-HT1A-R. All seven tested hits bind to α1A-AR, with two compounds displaying K i values below 1 μM, and a further two K i values of around 10 μM. The insights and knowledge gained through the development of the new 5-HT1A-R pharmacophores will greatly aid in the design and synthesis of derivatives of our lead compound, and allow the generation of more efficacious and selective ligands.
Collapse
|
7
|
Abel AS, Averin AD, Maloshitskaya OA, Savelyev EN, Orlinson BS, Novakov IA, Beletskaya IP. Palladium-catalyzed amination of dichloroquinolines with adamantane-containing amines. Molecules 2013; 18:2096-109. [PMID: 23389254 PMCID: PMC6270357 DOI: 10.3390/molecules18022096] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2012] [Revised: 01/24/2013] [Accepted: 02/01/2013] [Indexed: 01/10/2023] Open
Abstract
Pd-catalyzed amination of isomeric 2,6-, 2,8-, 4,8- and 4,7-dichloroquinolines was studied using adamantane-containing amines in which substituents at the nitrogen atom differ in bulkiness. The selectivity of the amination of 2,6-dichloroquinoline was very low, substantially better results were obtained with 2,8-dichloroquinoline, and 4,8- and 4,7-dichloroquinolines provided the best yields of the amination products. Diamination of 4,8- and 4,7-dichloroquinolines was carried out with two amines which differ strongly in the bulkiness of the alkyl group. In the majority of cases BINAP ligand was successfully applied, however, it had to be replaced with DavePhos in certain reactions when using the most sterically hindered amine as well as for the diamination reactions.
Collapse
Affiliation(s)
- Anton S. Abel
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, Moscow 119991, Russia; E-Mails: (A.S.A.); (O.A.M.); (I.P.B.)
| | - Alexei D. Averin
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, Moscow 119991, Russia; E-Mails: (A.S.A.); (O.A.M.); (I.P.B.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +7-495-939-1139; Fax: +7-495-939-3618
| | - Olga A. Maloshitskaya
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, Moscow 119991, Russia; E-Mails: (A.S.A.); (O.A.M.); (I.P.B.)
| | - Evgenii N. Savelyev
- Volgograd State Technical University, 28 Lenina prosp., Volgograd 400131, Russia; E-Mails: (E.N.S.; B.S.O.); (I.A.N)
| | - Boris S. Orlinson
- Volgograd State Technical University, 28 Lenina prosp., Volgograd 400131, Russia; E-Mails: (E.N.S.; B.S.O.); (I.A.N)
| | - Ivan A. Novakov
- Volgograd State Technical University, 28 Lenina prosp., Volgograd 400131, Russia; E-Mails: (E.N.S.; B.S.O.); (I.A.N)
| | - Irina P. Beletskaya
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, Moscow 119991, Russia; E-Mails: (A.S.A.); (O.A.M.); (I.P.B.)
| |
Collapse
|
8
|
Cimarosti Z, Rossi S, Tramarin D, Laval G, Stabile P, Giubellina N, Maton W, Allieri B, Campi F, Cooke J, Westerduin P. Application of the Quality by Design Principles for the Development of the Crystallization Process for a Piperazinyl-Quinoline and Definition of the Control Strategy for Form 1. Org Process Res Dev 2012. [DOI: 10.1021/op300126e] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Zadeo Cimarosti
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Sara Rossi
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Davide Tramarin
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Gilles Laval
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Paolo Stabile
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Nicola Giubellina
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - William Maton
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Brigida Allieri
- Pharmaceutical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming
4, 37135 Verona, Italy
| | - Francesca Campi
- Pharmaceutical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming
4, 37135 Verona, Italy
| | - Jason Cooke
- Chemical Development, Medicines Research Centre, GlaxoSmithKline, Stevenage, U.K
| | - Pieter Westerduin
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| |
Collapse
|
9
|
Okada E, Shibata D, Médebielle M, Hatakenaka M. A Facile and Convenient Method for the Synthesis of 6,8-Bis(trifluoroacetyl)quinolin-5-amines. HETEROCYCLES 2012. [DOI: 10.3987/com-11-s(p)38] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
10
|
Cimarosti Z, Giubellina N, Stabile P, Laval G, Tinazzi F, Maton W, Pachera R, Russo P, Moretti R, Rossi S, Cooke JWB, Westerduin P. Route Selection and Process Development for a 5-Piperazinylquinaldine Derivative for the Treatment of Depression and Anxiety. Org Process Res Dev 2011. [DOI: 10.1021/op200140v] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Zadeo Cimarosti
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Nicola Giubellina
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Paolo Stabile
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Gilles Laval
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Francesco Tinazzi
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - William Maton
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Roberta Pachera
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Paola Russo
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Ramona Moretti
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Sara Rossi
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Jason W. B. Cooke
- Chemical Development, Medicines Research Centre, GlaxoSmithKline, Stevenage, U.K
| | - Pieter Westerduin
- Chemical Development, GlaxoSmithKline Medicines Research Centre, Via Fleming 4, 37135 Verona, Italy
| |
Collapse
|
11
|
Roughley SD, Jordan AM. The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates. J Med Chem 2011; 54:3451-79. [PMID: 21504168 DOI: 10.1021/jm200187y] [Citation(s) in RCA: 1710] [Impact Index Per Article: 131.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
| | - Allan M. Jordan
- Cancer Research UK Drug Discovery Unit, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester, M20 4BX, U.K
| |
Collapse
|
12
|
5-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2(1H)-quinolinones and 3,4-dihydro-2(1H)-quinolinones: Dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors. Part 3. Bioorg Med Chem Lett 2010; 20:7092-6. [DOI: 10.1016/j.bmcl.2010.09.085] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2010] [Revised: 09/14/2010] [Accepted: 09/15/2010] [Indexed: 11/24/2022]
|
13
|
Leslie CP, Biagetti M, Bison S, Bromidge SM, Di Fabio R, Donati D, Falchi A, Garnier MJ, Jaxa-Chamiec A, Manchee G, Merlo G, Pizzi DA, Stasi LP, Tibasco J, Vong A, Ward SE, Zonzini L. Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, Selective, and Orally Active 5-HT1A/B/D Receptor Antagonist. J Med Chem 2010; 53:8228-40. [DOI: 10.1021/jm100714c] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Colin P. Leslie
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Matteo Biagetti
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Silvia Bison
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Steven M. Bromidge
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom
| | - Romano Di Fabio
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Daniele Donati
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Alessandro Falchi
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Martine J. Garnier
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Albert Jaxa-Chamiec
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Gary Manchee
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Giancarlo Merlo
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Domenica A. Pizzi
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Luigi P. Stasi
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Jessica Tibasco
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| | - Antonio Vong
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom
| | - Simon E. Ward
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom
| | - Laura Zonzini
- Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
| |
Collapse
|
14
|
Bromidge SM, Arban R, Bertani B, Bison S, Borriello M, Cavanni P, Dal Forno G, Di-Fabio R, Donati D, Fontana S, Gianotti M, Gordon LJ, Granci E, Leslie CP, Moccia L, Pasquarello A, Sartori I, Sava A, Watson JM, Worby A, Zonzini L, Zucchelli V. Design and Synthesis of Novel Tricyclic Benzoxazines as Potent 5-HT1A/B/D Receptor Antagonists Leading to the Discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045). J Med Chem 2010; 53:5827-43. [DOI: 10.1021/jm100482n] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Steven M. Bromidge
- Neurosciences CEDD, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, U.K
| | - Roberto Arban
- Medicines Research Centre, Via A. Fleming 4, Verona 37135, Italy
| | - Barbara Bertani
- Medicines Research Centre, Via A. Fleming 4, Verona 37135, Italy
| | - Silvia Bison
- Medicines Research Centre, Via A. Fleming 4, Verona 37135, Italy
| | | | - Paolo Cavanni
- Medicines Research Centre, Via A. Fleming 4, Verona 37135, Italy
| | | | - Romano Di-Fabio
- Medicines Research Centre, Via A. Fleming 4, Verona 37135, Italy
| | - Daniele Donati
- Medicines Research Centre, Via A. Fleming 4, Verona 37135, Italy
| | - Stefano Fontana
- Medicines Research Centre, Via A. Fleming 4, Verona 37135, Italy
| | - Massimo Gianotti
- Medicines Research Centre, Via A. Fleming 4, Verona 37135, Italy
| | - Laurie J. Gordon
- Neurosciences CEDD, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, U.K
| | - Enrica Granci
- Medicines Research Centre, Via A. Fleming 4, Verona 37135, Italy
| | - Colin P. Leslie
- Medicines Research Centre, Via A. Fleming 4, Verona 37135, Italy
| | - Luca Moccia
- Medicines Research Centre, Via A. Fleming 4, Verona 37135, Italy
| | | | - Ilaria Sartori
- Medicines Research Centre, Via A. Fleming 4, Verona 37135, Italy
| | - Anna Sava
- Medicines Research Centre, Via A. Fleming 4, Verona 37135, Italy
| | - Jeannette M. Watson
- Neurosciences CEDD, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, U.K
| | - Angela Worby
- Neurosciences CEDD, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, U.K
| | - Laura Zonzini
- Medicines Research Centre, Via A. Fleming 4, Verona 37135, Italy
| | | |
Collapse
|
15
|
Giubellina N, Stabile P, Laval G, Perboni AD, Cimarosti Z, Westerduin P, Cooke JWB. Development of an Efficient Large-Scale Synthesis for a 4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide Derivative for Depression and Anxiety. Org Process Res Dev 2010. [DOI: 10.1021/op100103v] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Nicola Giubellina
- Chemical Development, GlaxoSmithKline Medicine Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Paolo Stabile
- Chemical Development, GlaxoSmithKline Medicine Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Gilles Laval
- Chemical Development, GlaxoSmithKline Medicine Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Alcide D. Perboni
- Chemical Development, GlaxoSmithKline Medicine Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Zadeo Cimarosti
- Chemical Development, GlaxoSmithKline Medicine Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Pieter Westerduin
- Chemical Development, GlaxoSmithKline Medicine Research Centre, Via Fleming 4, 37135 Verona, Italy
| | - Jason W. B. Cooke
- Chemical Development, GlaxoSmithKline Medicine Research Centre, Via Fleming 4, 37135 Verona, Italy
| |
Collapse
|
16
|
Bromidge SM, Bertani B, Borriello M, Bozzoli A, Faedo S, Gianotti M, Gordon LJ, Hill M, Zucchelli V, Watson JM, Zonzini L. 8-[2-(4-Aryl-1-piperazinyl)ethyl]-2H-1,4-benzoxazin-3(4H)-ones: Dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors—Part II. Bioorg Med Chem Lett 2009; 19:2338-42. [DOI: 10.1016/j.bmcl.2009.02.056] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2008] [Revised: 02/12/2009] [Accepted: 02/13/2009] [Indexed: 11/25/2022]
|